Cross-Sector entity

Exact Sciences

Company EXAS
5.7

Exact Sciences is most often covered alongside Abbott Laboratories, which appears in 3 of these 7 stories. Across a 164-day span, the pace is roughly 0.3 stories per week. The busiest single day carried 2. The clearest coverage concentration is market-trends: 3 of 7 stories, with the rest divided among 3 other categories.

7 verified stories tracked

Last mentioned: 1d ago

RSS updates
Share

Entity pulse

Recent coverage · Exact Sciences

↑
7 stories
5.7 avg impact
57% positive
14% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 43 percentage points.

  • 57% positive
  • 29% neutral
  • 14% negative

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Exact Sciences

Exact Sciences is most often covered alongside Abbott Laboratories, which appears in 3 of these 7 stories. Across a 164-day span, the pace is roughly 0.3 stories per week. The busiest single day carried 2. The clearest coverage concentration is market-trends: 3 of 7 stories, with the rest divided among 3 other categories. Each carries 2.4 original sources on average. Negative sentiment appears in 14% of the tracked stories. We currently track 7 Cross-Sector stories that mention Exact Sciences, published between March 14, 2026 and August 24, 2026.

Stories tracked
7
Per week
0.3
Negative
14%
Sources per story
2.4

Computed from the 7 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Exact Sciences. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Global Milestone Announcement

    Gene Solutions issues press release detailing ASCO recognition, FDA designation, and IPO plans, marking a turning point for the company.

  2. FDA Breakthrough Device Designation

    The U.S. FDA grants Breakthrough Device Designation to SPOT-MAS 10, acknowledging its potential to address unmet needs in cancer screening.

  3. ASCO Breakthrough 2026

    Gene Solutions presents interim real-world data from 84,145 asymptomatic individuals for SPOT-MAS 10 at the ASCO Breakthrough conference in Singapore.

Stories mentioning Exact Sciences 7

Healthcare market trends Neutral 5

Abbott's 42% Diagnostics Surge vs Thermo Fisher's Recovery: Which Wins?

For health system executives, clinical lab directors, and healthcare investors, this comparison is a real-world barometer of whether diversified diagnostic platforms or life sciences recovery will shape vendor and research spending. Abbott's 42% diagnostics jump to $3.09B, driven by Cologuard and Exact Sciences, points to durable non-invasive screening demand. Thermo Fisher's improving pharma and biotech activity signals a potential rebound in research tool budgets.

2 sources

Source: insidermonkey.com · finance.yahoo.com

Healthcare medical devices Positive 6

Abbott lifts 2026 EPS forecast to $5.45-$5.60 on 9% device growth

Abbott raises its 2026 profit outlook as medical device sales jump 9% to $5.85B and diabetes care climbs 11%, proving the resilience of advanced cardiac and CGM technologies. The beat and guidance hike signal that hospitals continue to prioritize high-acuity procedures even under volume pressure.

2 sources